- Open Access
Gastrin-releasing peptide receptor expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study
Respiratory Research volume 13, Article number: 9 (2012)
Normal bronchial tissue expression of GRPR, which encodes the gastrin-releasing peptide receptor, has been previously reported by us to be associated with lung cancer risk in 78 subjects, especially in females. We sought to define the contribution of GRPR expression in bronchial epithelia to lung cancer risk in a larger case-control study where adjustments could be made for tobacco exposure and sex.
We evaluated GRPR mRNA levels in histologically normal bronchial epithelial cells from 224 lung cancer patients and 107 surgical cancer-free controls. Associations with lung cancer were tested using logistic regression models.
Bronchial GRPR expression was significantly associated with lung cancer (OR = 4.76; 95% CI = 2.32-9.77) in a multivariable logistic regression (MLR) model adjusted for age, sex, smoking status and pulmonary function. MLR analysis stratified by smoking status indicated that ORs were higher in never and former smokers (OR = 7.74; 95% CI = 2.96-20.25) compared to active smokers (OR = 1.69; 95% CI = 0.46-6.33). GRPR expression did not differ by subject sex, and lung cancer risk associated with GRPR expression was not modified by sex.
GRPR expression in non-cancerous bronchial epithelium was significantly associated with the presence of lung cancer in never and former smokers. The association in never and former smokers was found in males and females. Association with lung cancer did not differ by sex in any smoking group.
Lung cancer incidence rates have been declining for men since the 1980s. However, incidence rates for women over 65 have been increasing or have remained steady during this same time period . Though tobacco use is a significant risk factor for lung cancer, 15-20% of lung cancer patients are lifetime never-smokers. Our group previously reported that bronchial epithelium expression of GRPR, which encodes the gastrin-releasing peptide receptor (GRPR), was associated with a diagnosis of lung cancer in female never smokers . GRPR is an X-linked gene that has been reported to escape X-inactivation . This finding raised the possibility that increased GRPR expression in women accounted for some of the increased incidence rates of lung cancer in never smokers who are female, compared to never smoking men, which was recently reported in a large prospective cohort study . Since GRPR stimulation induces proliferative effects in bronchial cells , it is possible that activation of this pathway is a risk factor for lung cancer separate from that of tobacco exposure.
GRPR is overexpressed in lung cancers and in head and neck squamous cell carcinoma (HNSCC) [6, 7]. We have previously reported elevated levels of GRPR mRNA in lung cancers and HNSCC [6, 8]. In addition to cancer-specific overexpression of GRPR, we have demonstrated that mucosal tissues adjacent to HNSCC have GRPR mRNA levels reflective of the adjacent HNSCC tumor . These findings suggest that elevated GRPR mRNA in normal bronchial epithelia may be associated with lung cancer risk and/or may indicate the presence of lung cancer.
We undertook a case-control study to determine whether elevated GRPR mRNA expression in normal, at-risk epithelium correlated with the presence of lung cancer. We evaluated the association between GRPR mRNA expression in purified cultured normal bronchial epithelial cells and the presence of lung cancer. Our primary finding was the observed increased expression of GRPR in normal bronchial epithelia in lung cancer cases compared to cancer-free controls. The impact of this was highest in subjects who never smoked or who had undergone smoking cessation before diagnosis. The association was found in both male and female never smokers, suggesting GRPR plays a similar role in development of lung cancer in men and women. The result of this study highlights GRPR overexpression in normal epithelial mucosa as a candidate risk factor for lung cancer, especially in those with limited tobacco exposure.
Lung cancer case-control study subjects and tissues
Lung cancer cases (n = 224) and surgical control subjects (n = 107) enrolled in prospective thoracic surgical tissue collection protocols from 1992-2004 donated mainstem bronchus biopsy specimens obtained at the time of resection, bronchoscopy, or lung transplant. Questionnaire and pulmonary function tests were administered prior to surgery, and forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) were used to assess airway obstruction . Participants were patients with suspected lung cancer who underwent bronchoscopic or thoracic procedures. Cases had confirmed diagnoses of primary lung cancer while controls had non-cancerous diagnoses. Diagnoses occurring in 5% or more of surgical control subjects included the following: 15 had no diagnosis of disease (14%), 12 had emphysema (11%), 12 had a granuloma (11%), 11 had alpha-1 antitrypsin deficiency (10%), 7 had pulmonary hypertension (9%), 7 had a benign growth (7%), 6 had a lung obstruction (6%), 5 had cystic fibrosis (5%), 5 had a hamartoma (5%) and 5 had pulmonary fibrosis (5%). Two of the 15 control subjects with no diagnosis of disease were lung donors. Tissues from 219 of the 224 cases and 89 of the 107 controls were prospectively collected under protocols approved by the University of Pittsburgh institutional review board (IRB). In a cooperative effort, tissues from 5 of the 224 cases and 18 of the 107 controls were prospectively collected under a surveillance bronchoscopy protocol approved by the University of Colorado IRB. The case-control study populations are described in Table 1. Primary bronchial epithelial cell culture procedures were used to obtain proliferating bronchial epithelial cells as described previously . Bronchial epithelial cell cultures were harvested at passage 1 for GRPR mRNA expression studies.
Detection of GRPRexpression in bronchial epithelial cells
RNA isolation from bronchial cells and detection of GRPR gene expression was performed as previously described . PCR amplification was performed following oligo-dT-primed reverse transcription (RT) of total RNA using primers GRPR-1 (5'-CTCCCCGTGAACGATGACTGG-3') and GRPR-2 (5'-ATCTTCATCAGGGCATGGGAG-3'). Presence of GRPR product was evaluated by hybridization with a 32P-labeled internal probe (5'-CACCTCCATGCTCCACTTTGTC-3'). The GAPDH gene expression was also evaluated in order to assess RNA integrity and success of the reverse transcription step. GAPDH was successfully amplified from RNA isolated from all cases and controls.
In order to test the association of sex and other variables with GRPR bronchial expression, candidate confounding variables including age, sex, ethnicity, smoking status, pack-years of tobacco-use (py), and pulmonary function were evaluated for association with GRPR expression separately for cases and controls for each case-control study using the chi-square test, Fisher's exact test, or Wilcoxon rank sum test as appropriate. All P values reported were 2-sided with significance defined by P < 0.05.
Evaluating GRPR expression in non-cancerous bronchial epithelia among cases versus controls was the primary endpoint of the study. Univariate and multivariable logistic regression models were implemented to assess the significance of the association of GRPR bronchial expression with cancer before and after controlling for other important variables. For these models, age and sex were defined a priori to be included. Sex, ethnicity and smoking status were treated as categorical variables, age and pack-years as continuous variables, and pulmonary function as an ordinal variable. The likelihood ratio test was used to test the goodness of fit of logistic regression models. To assess whether the association between bronchial GRPR expression and lung cancer was modified by sex, a sex by GRPR expression interaction term was evaluated for significance in the multivariable logistic regression model. Because disease etiology likely differs for never smokers compared to smokers, a stratified analysis by smoking status was also performed.
Association of GRPR expression with overall survival, defined as time from surgery to death, was analyzed using Cox proportional hazards models. Date of surgery, death, and last follow-up were provided by the University of Pittsburgh Cancer Institute (UPCI) Lung Cancer Registrar. Hazard ratios associated with GRPR expression were estimated using multivariable Cox proportional hazards models. The assumption of proportional hazards was assessed for all Cox models by evaluation of scaled Schoenfeld residuals.
GRPR expression in bronchial epithelia was more frequent in lung cancer patients than cancer-free control subjects
Presence or absence of GRPR mRNA in non-cancerous bronchial epithelial cells derived from mainstem bronchus airway biopsies of lung cancer cases (n = 224) and cancer-free controls (n = 107) (Table 1) was assessed by RT-PCR followed by hybridization with a radio-labeled probe in order to maximize sensitivity. Because the airway biopsy analysis of this cohort began before quantitative PCR (q-PCR) was available, the RT-PCR semi-quantitative technique was used throughout the lung cancer case-control study to maintain consistency and power. Of the 224 lung cancer cases evaluated, 158 (71%) had GRPR expression in bronchial cells. In contrast, only 41 (38%) of the 107 cancer-free surgical controls had detectable GRPR bronchial expression.
GRPR expression has been reported to be elevated with tobacco use. We tested for association between GRPR expression in non-cancerous surrogate tissues and smoking status and pack-years of tobacco use stratified by cancer status. Among never and former smokers, lung cancer patients more frequently had detectable GRPR expression while the frequency of detected GRPR mRNA was similar for actively smoking lung cancer cases and controls (Table 2). We observed a statistically significant association between GRPR expression in bronchial mucosa and smoking status among lung cancer patients (P = 0.03, Table 2) with overrepresentation of GRPR bronchial expression among never smoking lung cancer patients. GRPR bronchial expression was also associated with smoking status among cancer-free surgical controls with an overrepresentation of GRPR bronchial expression among active smokers (P = 0.02) (Table 2). Only a minority of the never smoker and former smoker surgical cancer-free control subjects had GRPR bronchial expression while, the majority of actively smoking surgical controls had detectable GRPR bronchial expression. Though there was a significant association between GRPR expression and smoking status for cases and controls, in the analyses stratified by case status we found no statistically significant association between pack-years of smoking and GRPR expression in cases or controls (Table 2).
Bronchial GRPR expression was not associated with sex, ethnicity or pulmonary function in lung cancer cases or controls
In order to assess the association of subject characteristics with GRPR expression independent of cancer, a stratified analysis by case status was performed separately for the lung cancer case and control populations. We hypothesized that GRPR expression would differ by sex because GRPR resides on the portion of the X chromosome reported to escape X-inactivation , and we had previously reported that GRPR expression in bronchial tissues was more frequent in women never smokers than men never smokers in a study involving 78 subjects .
In this larger study involving 331 subjects, in addition to evaluating differences in GRPR expression by sex, we also tested the association between GRPR expression and age, ethnicity and pulmonary function. GRPR bronchial expression levels did not differ by sex, ethnicity or pulmonary function for either lung cancer cases or controls (Table 2). However, lung cancer cases positive for GRPR expression were statistically younger than GRPR negative cases (Table 2).
Evaluating the GRPR expression distribution among surgical cancer-free controls by benign diagnosis, we observed a trend towards a significant association (p = 0.065, Fisher's exact test) with deviations from the average 38% GRPR positive frequency being most apparent for diagnoses of alpha-1 trypsin deficiency (1 of 11 subjects were GRPR positive) and granuloma (9 of 12 subjects were GRPR positive). Only two of the 9 GRPR positive granuloma subjects were active smokers. This trend towards increased bronchial GRPR expression in subjects with granuloma that did not reach statistical significance suggests the possibility that inflammation-induced tissue damage and/or wound repair in response to damage may be associated with bronchial GRPR expression. We did not find evidence of an association between bronchial GRPR expression and hyperproliferative disorders among the cancer-free control subjects.
GRPR expression levels did not reflect disease stage or tumor type
In order to determine whether GRPR expression differed by tumor clinical and/or pathological characteristics, we tested for association between tumor characteristics and bronchial GRPR expression in lung cancer cases. The distribution of lung cancer cases by clinical stage and tumor histology is provided in Table 1. Bronchial GRPR expression in non-cancerous mucosa was independent of disease stage (P = 0.49, Table 2) and tumor histology (P = 0.50, Table 2).
GRPR expression in non-cancerous bronchial mucosal tissues was significantly associated with lung cancer independent of age, sex and smoking status
Detection of GRPR mRNA in bronchial tissues was significantly associated with presence of lung cancer (O.R = 3.85; 95% CI = 2.37-6.25) (All Subjects, Figure 1). Even after controlling for possible confounding effects of age, sex, smoking status and pulmonary function expression of GRPR in normal bronchial epithelium remained significantly associated with lung cancer (O.R. = 4.76; 95% CI = 2.32-9.77) (All Subjects, Figure 1). GRPR was previously reported by our group in a study of 78 subjects to be more frequently expressed in women with lung cancer than in men with lung cancer , suggesting the possibility that this differential expression may account at least in part for the heightened smoking-related lung cancer risk for women observed in some studies [10, 11]. However, in this larger study, the pair-wise interaction between sex and GPRR expression was found not to be significant (P = 0.31) in a multivariable logistic regression model also containing age, sex, pulmonary function and bronchial GRPR expression. Therefore, this study did not support our previous hypothesis that GRPR expression among women contributed to their increased lung cancer risk. Rather, it suggested that never smoking status was a confounder in our previous analysis, since the majority of never smokers diagnosed with lung cancer are female.
GRPR expression in bronchial epithelium was significantly associated with lung cancer among never smokers and former smokers but not active smokers
Molecular alterations differ markedly for tobacco-related versus non-tobacco-related lung cancers [12, 13]. These finding indicate that disease etiology for lung cancer varies by tobacco-use history. A stratified analysis by smoking status indicated that presence of GRPR expression in bronchial cells was significantly associated with lung cancer for never smokers (O.R. = 17.0; 95% C.I = 3.32-87.13) and former smokers (O.R. = 3.69; 95% C.I = 1.88-7.29) but not active smokers (O.R. = 1.18; 95% CI = 0.34-4.15) (Figure 1), and these odds ratios differed significantly (P < 0.001, Mantel-Haenszel test of homogeneity (M-H test)). The association between GRPR bronchial expression and lung cancer among never smokers and former smokers was significant even after controlling for the effects of age, sex, and pulmonary function (Figure 1). The combined, adjusted odds ratio for never and former smokers, which were found to not differ significantly (P = 0.09; M-H test), was 7.74 (95% CI = 2.96-20.25). A trend towards higher odds ratios with fewer pack-years of tobacco use was observed when the analysis was stratified by tertiles of control subject pack-year use (data not shown); however, the odds ratios did not differ significantly by tertile pack-year category.
Because we hypothesized that GRPR expression in bronchial epithelia would contribute to increased risk of lung cancer for women never smokers compared to men never smokers, we tested the interaction between sex and GRPR expression status for association with lung cancer in the never smoking stratum. We found the GRPR expression by sex interaction to not be significantly associated with lung cancer among never smokers in a multiple logistic regression model also containing age, sex and pulmonary function (P = 0.94). Because the number of never smokers in our study was not large (n = 52) and the association between GRPR expression and lung cancer did not differ significantly between never and former smokers, we also tested the GRPR expression by sex interaction for significance for never and former smokers. We found that the GRPR expression by sex interaction was also not significant in this same model when evaluating never and former smokers (P = 0.47).
GRPR expression in surrogate tissues was not a prognostic indicator for survival in lung cancer cases
Because GRPR expression in bronchial epithelia was associated with lung cancer, we hypothesized that for cases with detectable bronchial GRPR expression, survival would be reduced compared to cases without detectable GRPR expression. However, the presence of GRPR mRNA in bronchial cells was not an indication of overall lung cancer survival. The hazards ratio for overall lung cancer survival in Cox models adjusted for age, sex, and disease stage was 0.87 (95% CI = 0.57-1.34) for patients with GRPR bronchial expression compared to patients without detectable GRPR bronchial expression.
In lung cancer GRPR and its ligand are involved in autocrine growth stimulation [6, 14]. Previous results showed that lung tumor tissues have elevated GRPR expression, and we have previously described elevated GRPR mRNA levels in histologically normal mucosal tissues adjacent to HNSCC compared to oral mucosal tissues from cancer-free control subjects . GRPR mRNA expression has also been detected in prostate tumors and tissues adjacent to prostate cancers . Our new findings reported here indicate that in a prospectively collected lung cancer case-control population, GRPR expression in at-risk upper aerodigestive mucosa was significantly associated with lung cancer. Importantly, even after controlling for the effects of possible confounding by age, sex, and tobacco use, GRPR expression in non-cancerous mucosal tissues was significantly associated with lung cancer among never and former smokers and appeared to confer similar risk to both sexes.
Our finding here of no difference in bronchial epithelial cell GRPR expression between men and women did not replicate our previous result . In our previous bronchial cell study, which had a smaller sample size of 78 patients, the presence of cancer was not separately evaluated, and only one never smoker with lung cancer was male . In retrospect, it is likely that the associations between GRPR expression, female sex, and smoking observed in our previous study were actually surrogates for the underlying association between bronchial epithelial GRPR expression and lung cancer, which appears to be most significant in never smokers. Therefore, this study presents important revisions to our previous understanding of the role of GRPR in lung cancers arising in females and males; this study supports a similar role for bronchial GRPR mRNA expression and lung cancer risk for both females and males.
Although in the current study we also found no association between GRPR expression and pack-years of smoking, we did observe associations between smoking status (active versus former smoker versus never smoker) and GPRR expression. We observed these associations for both cases and controls separately, but the relationships were different. The proportion of GRPR positive actively smoking cancer-free control subjects was similar to the proportion of actively smoking lung cancer cases. These findings were consistent with our previously reported findings that GRPR expression in bronchial epithelium was activated with tobacco use  and with findings that bombesin-like peptide receptors play a role in wound healing following airway injury . Similar to our previous findings of persistent bronchial GRPR expression after tobacco cessation , we detected bronchial GRPR expression in the majority of former smoking lung cancer cases. In contrast, in the current study bronchial GRPR expression was detected in only a minority of cancer-free controls who were former smokers. The inclusion of more cancer-free control subjects in this study compared to our 1997 study has allowed us to evaluate lung cancer patients and cancer-free controls separately and has revealed new insights regarding the relationship between bronchial GRPR expression and tobacco use in cancer-free controls.
Although the number of active smoking surgical controls in our current study was small, the data suggest that bronchial GRPR expression may be induced by tobacco use in subjects without lung cancer, but that the increase in GRPR expression in bronchial mucosa likely subsides following the cessation of smoking in most subjects without lung cancer. Among former smoking lung cancer cases, bronchial GRPR expression may be aberrantly maintained following cessation of smoking, or similar to never smoking lung cancer cases, bronchial GRPR expression may reflect risk that is independent of tobacco use. Our 1997 report indicated that of the 4 cancer-free subjects with defined bronchial GRPR expression and smoking status, 1 active smoker was GRPR positive while 3 subjects who were former or never smokers were negative for GRPR expression. Therefore, although the numbers are small, among cancer-free control subjects, the relationship between smoking status and bronchial GRPR expression in the 1997 study is consistent with our current study results.
Of special interest was the finding of frequent bronchial GRPR expression among never smoking lung cancer cases. While GRPR expression was detected in only a minority of never smoking cancer-free controls, GRPR expression was detected in almost 90% of never smoking lung cancer cases. Though the specific cause of GRPR expression in never smoking lung cancer cases is unknown, we posit that bronchial GRPR expression may reflect an inherent or conferred risk factor that can be best observed in the absence of the more potent risk factor of tobacco use. Though bronchial GRPR expression was more common among cancer-free controls with a diagnosis of granuloma, suggesting a possible inflammatory component to bronchial GRPR expression among cancer-free controls, bronchial GRPR expression was not increased in lung cancer cases or controls with more severe pulmonary obstruction, which also has an inflammatory component. Therefore, the role of inflammation in elevated bronchial GRPR expression remains undefined.
GRPR expression in normal bronchial tissues was not correlated with clinical disease stage. Therefore, our data suggest that GRPR expression in surrogate tissues did not reflect tumor burden and, perhaps, was not a direct consequence of the prevalent cancer. Our finding that detectable GRPR expression in normal upper aerodigestive tissues was not an indication of poor overall survival for lung cancer cases indicates that elevated GRPR bronchial cell expression was not associated with disease progression and is, instead, likely to be a marker of risk exposure or a marker of host susceptibility.
Lung cancer cases positive for GRPR bronchial expression were significantly younger than cases negative for GRPR expression, which supports the role of GRPR bronchial expression as conferring lung cancer risk. Though a prospective cohort study will be required to fully understand the relationship between GRPR expression levels in surrogate tissues and the development of lung cancer, GRPR expression in normal bronchial tissues has potential value as a marker for elevated risk, especially in those with little or no tobacco exposure. Though GRPR is overexpressed in many solid tumors, only one other group has evaluated GRPR, GRP and/or their gene product levels in surrogate tissues of cancer patients to date. Uchida et al. reported that serum levels of proGRP, as measured by enzyme-linked immunosorbent assay (ELISA), correlated with tumor GRP gene expression levels in small cell lung cancer (SCLC) patients . GRPR expression levels in tumors were not evaluated in our study, as material for analysis was not available.
The increased risk due to elevated GRPR expression may be most apparent in never and former smokers because the contribution of GRPR expression to risk is obscured in active smokers by factors such as genetic abnormalities and inflammatory processes that confer substantial risk from tobacco use. Elevated GRPR expression in the lung may independently contribute to increased cancer risk by promoting proliferation. GRPR is expressed at early embryonic stages in the nervous, urogenital, respiratory, and gastrointestinal systems and expression in these tissues is generally down-regulated before birth [18–20]. The GRPR ligand, GRP, a bombesin-like peptide (BLP) growth factor, is expressed by pulmonary neuroendocrine cells and has been shown to stimulate lung development in utero and to increase growth and maturation of human fetal lung organ cultures [20, 21]. In non-cancerous tissues, BLPs stimulate growth of bronchial, gastrointestinal and pancreatic epithelial cells and lead to ligand-dependent hyperplasia [5, 19, 22–24]. GRPR and GRP are involved in an autocrine stimulation loop in lung cancer and HNSCC [6, 14], and GRPR expression has been shown to be positively regulated by GRP . Increased GRPR expression in the lung may, therefore, reflect a state that is more nascent and proliferative in nature than epithelium with low or undetected GRPR expression.
We acknowledge our case-control study population limitations. This case-control study required hospital surgical controls, and this limited recruitment with the result that our lung cancer cases are older than our controls and include fewer men. In addition, the exhaustion of samples made quantitative measurements of GRPR mRNA expression impossible. We have confined our analysis to GRPR mRNA because of antibody reagent limitations at the time the samples were evaluated. This leaves the question of whether GRPR protein levels also differ unanswered. Despite these limitations, a high degree of association between detectable GRPR expression in normal bronchial tissue and lung cancer was demonstrated in the case-control population even after adjusting for sex and age.
Though we did not assess the epidermal growth factor receptor (EGFR) mRNA or protein expression in bronchial epithelial cultures, we speculate that increased GRPR expression contributes to lung cancer through EGFR-dependent and/or -independent mechanisms. The EGFR pathway has been reported to be activated in lung tumors from never smokers with EGFR mutations, and it is possible that lung tumors developing in never smokers have multiple mechanisms for EGFR activation. The GRPR pathway is known to interact with the EGFR pathway in lung cancer cells by increasing the release of EGFR ligands such as amphiregulin , which could act to further promote cancer in never smokers who develop EGFR mutations. Alternatively, activation of the GRPR pathway may increase EGFR bronchial cell signaling in the absence of EGFR mutation, providing another route to lung cancer development in never smokers.
The GRPR pathway may activate proliferative pathways that increase the likelihood of lung cancer development in male and female former and never smokers. We conclude from our data that GRPR expression likely does not contribute to sex differences in rates of lung cancer incidence in never or former smokers.
forced expiratory volume in the first second
forced vital capacity
gastrin-releasing peptide receptor
head and neck squamous cell carcinoma
test Mantel-Haenszel test of homogeneity
Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlander N, Eisner MP, Reichman M, Edwards BK: SEER Cancer Statistics Review. 2007
Shriver SP, Bourdeau HA, Gubish CT, Tirpak DL, Davis AL, Luketich JD, Siegfried JM: Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J Natl Cancer Inst. 2000, 92: 24-33. 10.1093/jnci/92.1.24.
Ishikawa-Brush Y, Powell JF, Bolton P, Miller AP, Francis F, Willard HF, Lehrach H, Monaco AP: Autism and multiple exostoses associated with an X;8 translocation occurring within the GRPR gene and 3' to the SDC2 gene. Hum Mol Genet. 1997, 6: 1241-1250. 10.1093/hmg/6.8.1241.
Freedman ND, Leitzmann MF, Hollenbeck AR, Schatzkin A, Abnet CC: Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol. 2008, 9: 649-656. 10.1016/S1470-2045(08)70154-2.
Siegfried JM, DeMichele MA, Hunt JD, Davis AG, Vohra KP, Pilewski JM: Expression of mRNA for gastrin-releasing peptide receptor by human bronchial epithelial cells. Association with prolonged tobacco exposure and responsiveness to bombesin-like peptides. Am J Respir Crit Care Med. 1997, 156: 358-366.
Lango MN, Dyer KF, Lui VW, Gooding WE, Gubish C, Siegfried JM, Grandis JR: Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 2002, 94: 375-383. 10.1093/jnci/94.5.375.
Corjay MH, Dobrzanski DJ, Way JM, Viallet J, Shapira H, Worland P, Sausville EA, Battey JF: Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells. J Biol Chem. 1991, 266: 18771-18779.
Liu X, Carlisle DL, Swick MC, Gaither-Davis A, Grandis JR, Siegfried JM: Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib. Exp Cell Res. 2007, 313: 1361-1372. 10.1016/j.yexcr.2007.01.016.
Zielinski J, Bednarek M: Early detection of COPD in a high-risk population using spirometric screening. Chest. 2001, 119: 731-736. 10.1378/chest.119.3.731.
Risch HA, Howe GR, Jain M, Burch JD, Holowaty EJ, Miller AB: Lung cancer risk for female smokers. Science. 1994, 263: 1206-1208. 10.1126/science.8122096.
Zang EA, Wynder EL: Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst. 1996, 88: 183-192.
Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, Rosell R, Monzo M, Wu L, Westra WH, Yang SC, Jen J, Sidransky D: Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Research. 2001, 61: 1309-1313.
Sun S, Schiller JH, Gazdar AF: Lung cancer in never smokers--a different disease. Nature Reviews Cancer. 2007, 7: 778-790. 10.1038/nrc2190.
Siegfried JM, Krishnamachary N, Gaither Davis A, Gubish C, Hunt JD, Shriver SP: Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer. Pulm Pharmacol Ther. 1999, 12: 291-302. 10.1006/pupt.1999.0210.
Bartholdi MF, Wu JM, Pu H, Troncoso P, Eden PA, Feldman RI: In situ hybridization for gastrin-releasing peptide receptor (GRP receptor) expression in prostatic carcinoma. Int J Cancer. 1998, 79: 82-90. 10.1002/(SICI)1097-0215(19980220)79:1<82::AID-IJC16>3.0.CO;2-J.
Tan YR, Qi MM, Qin XQ, Xiang Y, Li X, Wang Y, Qu F, Liu HJ, Zhang JS: Wound repair and proliferation of bronchial epithelial cells enhanced by bombesin receptor subtype 3 activation. Peptides. 2006, 27: 1852-1858. 10.1016/j.peptides.2005.12.012.
Uchida K, Kojima A, Morokawa N, Tanabe O, Anzai C, Kawakami M, Eto Y, Yoshimura K: Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer. J Cancer Res Clin Oncol. 2002, 128: 633-640. 10.1007/s00432-002-0392-8.
Battey J, Wada E, Wray S: Bombesin receptor gene expression during mammalian development. Ann N Y Acad Sci. 1994, 739: 244-252. 10.1111/j.1749-6632.1994.tb19826.x.
Xiao D, Wang J, Hampton LL, Weber HC: The human gastrin-releasing peptide receptor gene structure, its tissue expression and promoter. Gene. 2001, 264: 95-103. 10.1016/S0378-1119(00)00596-5.
Shan L, Emanuel RL, Dewald D, Torday JS, Asokanathan N, Wada K, Wada E, Sunday ME: Bombesin-like peptide receptor gene expression, regulation, and function in fetal murine lung. Am J Physiol Lung Cell Mol Physiol. 2004, 286: L165-173.
Sunday ME, Hua J, Dai HB, Nusrat A, Torday JS: Bombesin increases fetal lung growth and maturation in utero and in organ culture. Am J Respir Cell Mol Biol. 1990, 3: 199-205.
Siegfried JM, Guentert PJ, Gaither AL: Effects of bombesin and gastrin-releasing peptide on human bronchial epithelial cells from a series of donors: individual variation and modulation by bombesin analogs. Anat Rec. 1993, 236: 241-247. 10.1002/ar.1092360129.
Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD: Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature. 1985, 316: 823-826. 10.1038/316823a0.
Lehy T, Puccio F, Chariot J, Labeille D: Stimulating effect of bombesin on the growth of gastrointestinal tract and pancreas in suckling rats. Gastroenterology. 1986, 90: 1942-1949.
P50-CA090440 SPORE in Lung Cancer (JMS)
P50-CA058187 (SPORE in Lung Cancer at the Univerity of Colorado (YEM)
The authors would like to acknowledge Ms. Autumn Gaither Davis, Ms. Michele Tavlarides, Ms. Michele Silhanek, Ms. Toni Hopkins and Ms. Jennifer Ridge Hetrick for valuable technical assistance. We also thank Dr. Timothy Kennedy of the University of Colorado SPORE in Lung Cancer for providing some of the bronchial biopsies used in this study.
The authors declare that they have no competing interests.
AME contributed to the conception of analyses, performed analyses, interpreted statistical analyses and writing of the manuscript. AGD coordinated sample storage, retrieval and database. YS and SL performed statistical analyses. JMP, JDL, RD, YEM enrolled patients into the clinical trial, collected and provided specimens for analysis. JRG contributed to the conception and design of this project and contributing to the writing of this manuscript. JMS contributed to the conception and design of this project and contributed to the writing of this manuscript. All authors have read and approved the final manuscript
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Egloff, A.M., Gaither Davis, A., Shuai, Y. et al. Gastrin-releasing peptide receptor expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study. Respir Res 13, 9 (2012). https://doi.org/10.1186/1465-9921-13-9
- Gastrin-releasing peptide receptor
- lung cancer risk
- case-control study
- surrogate tissue